title: Secretory phospholipase A₂-mediated progression of hepatotoxicity initiated by acetaminophen is exacerbated in the absence of hepatic COX-2.
abstract: We have previously reported that among the other death proteins, hepatic secretory phospholipase A₂ (sPLA₂) is a leading mediator of progression of liver injury initiated by CCl₄ in rats. The aim of our present study was to test the hypothesis that increased hepatic sPLA₂ released after acetaminophen (APAP) challenge mediates progression of liver injury in wild type (WT) and COX-2 knockout (KO) mice. COX-2 WT and KO mice were administered a normally non lethal dose (400 mg/kg) of acetaminophen. The COX-2 KO mice suffered 60% mortality compared to 100% survival of the WT mice, suggesting higher susceptibility of COX-2 KO mice to sPLA₂-mediated progression of acetaminophen hepatotoxicity. Liver injury was significantly higher at later time points in the KO mice compared to the WT mice indicating that the abatement of progression of injury requires the presence of COX-2. This difference in hepatotoxicity was not due to increased bioactivation of acetaminophen as indicated by unchanged cyp2E1 protein and covalently bound ¹⁴C-APAP in the livers of KO mice. Hepatic sPLA₂ activity and plasma TNF-α were significantly higher after APAP administration in the KO mice. This was accompanied by a corresponding fall in hepatic PGE₂ and lower compensatory liver regeneration and repair (³H-thymidine incorporation) in the KO mice. These results suggest that hindered compensatory tissue repair and poor resolution of inflammation for want of beneficial prostaglandins render the liver very vulnerable to sPLA₂-mediated progression of liver injury. These findings are consistent with the destructive role of sPLA₂ in the progression and expansion of tissue injury as a result of continued hydrolytic breakdown of plasma membrane phospholipids of perinecrotic hepatocytes unless mitigated by sufficient co-induction of COX-2.
authors.affiliation: Department of Toxicology, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71209-0470, USA.
authors.forename: Vishakha S
authors.initials: VS
authors.lastname: Bhave
authors.forename: Shashikiran
authors.initials: S
authors.lastname: Donthamsetty
authors.forename: John R
authors.initials: JR
authors.lastname: Latendresse
authors.forename: Michael L
authors.initials: ML
authors.lastname: Cunningham
authors.forename: Harihara M
authors.initials: HM
authors.lastname: Mehendale
mesh_terms: D000082:Acetaminophen / Q000633:toxicity*; D018712:Analgesics, Non-Narcotic / Q000633:toxicity*; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000209:etiology* / Q000503:physiopathology; D051546:Cyclooxygenase 2 / Q000235:genetics*; D015232:Dinoprostone / Q000378:metabolism; D018450:Disease Progression; D008115:Liver Regeneration / Q000502:physiology; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D054497:Phospholipases A2, Secretory / Q000378:metabolism*; D013534:Survival; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D018712:Analgesics, Non-Narcotic; D014409:Tumor Necrosis Factor-alpha; D000082:Acetaminophen; D051546:Cyclooxygenase 2; D054497:Phospholipases A2, Secretory; D015232:Dinoprostone